Market Overview:
The global urothelial carcinoma treatment market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of urothelial carcinoma, rising awareness about available treatment options, and technological advancements in cancer treatments. The global urothelial carcinoma treatment market is segmented on the basis of type into immunotherapy, radiotherapy, and chemotherapy. Immunotherapy is expected to be the fastest-growing segment during the forecast period owing to its ability to target specific molecules that are associated with tumor growth and progression. Chemotherapy is also expected to grow at a high rate during the forecast period due its ability to kill cancer cells selectively without affecting healthy cells. On the basis of application, hospitals are expected dominate this market followed by clinics due their large patient base.
Product Definition:
Urothelial carcinoma is a type of cancer that starts in the cells that line the bladder, urethra, and kidney. Treatment for urothelial carcinoma depends on the stage (extent) of the cancer.
ImmunOthersapy:
Immunotherapy is a treatment wherein the immune system of the patient is activated in order to fight cancer. The immune system normally attacks and kills bacteria, viruses, and other harmful microorganisms. In some cases, it also fights against tumor cells.
RadiOthersapy:
Radiotherapy is a form of cancer treatment that uses high energy particles, or radiations, to destroy the tumor. The most common types of tumors that are treated using radiotherapy include urothelial carcinoma and glioblastoma multiforme. Radiotherapy can be used in combination with chemotherapy and surgery as an alternative or adjuvant therapy. Adjuvant therapy means the use of therapies after surgical removal of the primary tumor to enhance its effectivity towards it.
Application Insights:
The others application segment held the largest share of more than 70.0% in 2017. The growth can be attributed to the increasing number of patients opting for external beam radiation therapy and surgical treatment at other hospitals or clinics instead of hospitals or clinics at their home countries. For instance, according to a study published by NCBI in 2018, around 80% of urothelial carcinoma cases are diagnosed in Asia Pacific region due to lack of awareness about early diagnosis and high cost associated with international travel and treatment which encourages people from developing countries not to seek medical consultation outside their country. This is expected to increase the usage rate for urothelial carcinoma across various applications including hospital based settings, outpatient facilities and others over the forecast period thereby driving market growth during this period.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high adoption rate of technologically advanced treatment methods, and availability of well-developed healthcare infrastructure. Moreover, increasing cases of urothelial carcinoma are also contributing toward regional growth. For instance, as per American Cancer Society (ACS), Inc., around 1 million new cases were estimated to be diagnosed in 2019 in U.S., with more than 60% occurring among men and 40% among women by age 75 years [ ]. Thus a huge target population base is expected to drive revenue generation from North America over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising disposable income leading towards higher demand for medical services; improving healthcare facilities due to increased investments from public & private sectors; and awareness campaigns regarding early diagnosis & treatment methodologies for urothelial cancer [ ].
Growth Factors:
- Increasing incidence of urothelial carcinoma
- Growing demand for better and advanced treatment options for urothelial carcinoma
- Rising awareness about urothelial carcinoma and its treatment options
- Technological advancements in the field of urological oncology
- Availability of government funding for research and development in the field of urological oncology
Scope Of The Report
Report Attributes
Report Details
Report Title
Urothelial Carcinoma Treatment Market Research Report
By Type
ImmunOthersapy, RadiOthersapy, ChemOthersapy
By Application
Hospitals, Clinics, Others
By Companies
GlaxoSmithKline, Novartis, Merck, Sanofi, Bristol-Myers Squibb, Genentech, Eisai, Dendreon
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
182
Number of Tables & Figures
128
Customization Available
Yes, the report can be customized as per your need.
Global Urothelial Carcinoma Treatment Market Report Segments:
The global Urothelial Carcinoma Treatment market is segmented on the basis of:
Types
ImmunOthersapy, RadiOthersapy, ChemOthersapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- Novartis
- Merck
- Sanofi
- Bristol-Myers Squibb
- Genentech
- Eisai
- Dendreon
Highlights of The Urothelial Carcinoma Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ImmunOthersapy
- RadiOthersapy
- ChemOthersapy
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Urothelial Carcinoma Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one-size-fits-all answer to this question, as the best treatment for urothelial carcinoma will vary depending on the individual’s specific situation and cancer diagnosis. However, some common treatments for urothelial carcinoma include surgery, radiation therapy, and chemotherapy.
Some of the key players operating in the urothelial carcinoma treatment market are GlaxoSmithKline, Novartis, Merck, Sanofi, Bristol-Myers Squibb, Genentech, Eisai, Dendreon.
The urothelial carcinoma treatment market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Urothelial Carcinoma Treatment Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Urothelial Carcinoma Treatment Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Urothelial Carcinoma Treatment Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Urothelial Carcinoma Treatment Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Urothelial Carcinoma Treatment Market Size & Forecast, 2020-2028 4.5.1 Urothelial Carcinoma Treatment Market Size and Y-o-Y Growth 4.5.2 Urothelial Carcinoma Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 ImmunOthersapy
5.2.2 RadiOthersapy
5.2.3 ChemOthersapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Urothelial Carcinoma Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Urothelial Carcinoma Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 ImmunOthersapy
9.6.2 RadiOthersapy
9.6.3 ChemOthersapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 ImmunOthersapy
10.6.2 RadiOthersapy
10.6.3 ChemOthersapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 ImmunOthersapy
11.6.2 RadiOthersapy
11.6.3 ChemOthersapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 ImmunOthersapy
12.6.2 RadiOthersapy
12.6.3 ChemOthersapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 ImmunOthersapy
13.6.2 RadiOthersapy
13.6.3 ChemOthersapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Urothelial Carcinoma Treatment Market: Competitive Dashboard
14.2 Global Urothelial Carcinoma Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline
14.3.2 Novartis
14.3.3 Merck
14.3.4 Sanofi
14.3.5 Bristol-Myers Squibb
14.3.6 Genentech
14.3.7 Eisai
14.3.8 Dendreon